search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Genetic testing in breast cancer patients based on a home information package: DNA-direct.


- candidate number10229
- NTR NumberNTR3018
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR10-aug-2011
- Secondary IDsNL36219.091.11 CCMO
- Public TitleGenetic testing in breast cancer patients based on a home information package: DNA-direct.
- Scientific TitleDNA-testing for BRCA1/2 in breast cancer patients prior to genetic counseling: DNA-direct.
- ACRONYMDNA-direct
- hypothesisThis study will offer breast cancer patients who are referred for genetic testing, the option of replacing initial face-to-face genetic counseling prior to DNA-testing (DNA-intake procedure) by an information package of telephone, written and digital information sent to their homes (DNA-direct procedure). We want to evaluate the effects of the DNA-direct procedure on the experience and psychosocial burden of breast cancer patients, as well as the speed and quality of genetic advice, as compared to the current DNA-intake procedure. We hypothesize that undergoing the DNA-direct procedure does not lead to increased levels of psychosocial burden as compared to the current DNA-intake procedure, showing equal levels of patient satisfaction plus shorter waiting and processing times. Thus, we expect DNA-direct to be an acceptable procedure for breast cancer patients to undergo genetic testing, leading to more customized care.
- Healt Condition(s) or Problem(s) studiedBreast cancer, Hereditary breast cancer, BRCA1/2
- Inclusion criteriaAll female breast cancer patients (recently diagnosed or in the past) referred to the department of Clinical Genetics of the Radboud University Medical Centre Nijmegen for genetic counseling.
- Exclusion criteria1. Problems with (large amounts of) written Dutch text;
2. Current psychological / psychiatric treatment (including medication);
3. Problems with family communication about cancer as estimated by the patient.
- mec approval receivedyes
- multicenter trialno
- randomisedno
- groupParallel
- Type2 or more arms, non-randomized
- Studytypeintervention
- planned startdate 8-aug-2011
- planned closingdate1-mei-2012
- Target number of participants150
- InterventionsDNA-direct procedure:
Replacing the current initial face-to-face consultation to provide general information about hereditary breast cancer and genetic testing (DNA-intake procedure), by a home information package of telephone, written and digital information (website and specially made educational movie). DNA-testing will be performed prior to face-to-face genetic counseling, contrary to the current practice (DNA-intake), where genetic counseling precedes DNA-testing. Disclosure of DNA-results will always follow in a face-to-face consultation in both DNA-direct and DNA-intake procedures.
- Primary outcome1. Satisfaction of the patient (i.e. RIVM-questionnaire, Decisional Conflict Scale, open-ended questions);
2. Psychological / psychosocial burden of the patient (i.e. Impact of Event Scale, questions regarding quality of life (selected from EORTC-QLQ C30), GHQ-12, Cancer Worry Scale, risk perception of hereditary and recurrent breast cancer on a scale of 0-100%).
- Secondary outcome1. Factors that determine the patientís choice for or against the DNA-direct procedure (i.e. demographic information, Empowerment (NEV-bk), open-ended questions);
2. Waiting and processing times;
3. Family characteristics of detected families with a mutation in the BRCA1 or BRCA2 gene (i.e. ODHCF).
- TimepointsAt inclusion (T0), baseline questionnaire:
1. General demographic information;
2. Psychological / psychosocial burden;
3. Empowerment.

After completion of genetic counseling (T1, at least 8 weeks after baseline), follow-up questionnaire:
1. Psychological / psychosocial burden;
2. Reasons for choosing for or against the DNA-direct procedure;
3. Satisfaction with genetic counseling and testing;
4. Personal experiences and satisfaction with chosen procedure;
5. Family relations and communication about cancer.

After completion of the follow-up questionnaire (T3), a small selection of patients receive an invitation for a 30 minute semistructured interview by telephone. Patients are selected for an interview if they are confirmed carriers of a BRCA1/2 mutation, if they report problems with the chosen procedure, or randomly (n=10).
- Trial web siteN/A
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIESMD. A.S. Sie
- CONTACT for SCIENTIFIC QUERIESProf. dr. N. Hoogerbrugge
- Sponsor/Initiator Radboud University Medical Center Nijmegen
- Funding
(Source(s) of Monetary or Material Support)
Radboud University Medical Centre Nijmegen
- PublicationsN/A
- Brief summaryThe aim of this study is to evaluate the effects of replacing face-to-face genetic counseling prior to genetic testing (DNA-intake procedure) by a home information package (DNA-direct procedure), on the satisfaction and psychological/psychosocial burden of breast cancer patients, as well as the speed and quality of genetic advice. 150 patients who are or have been in treatment for breast cancer and are referred to the department of Clinical Genetics of the Radboud University Medical Centre (Nijmegen, the Netherlands) for genetic counseling, may choose between the DNA-intake or DNA-direct procedures, prior to DNA-testing. All patients included should not have problems with Dutch text or with family communication, nor be in treatment for psychological/psychiatric diseases. All patients receive the same two questionnaires when included (baseline) and after completion of genetic counseling (follow-up). A small selection of patients is also invited for a semistructured interview by telephone. By offering the DNA-direct procedure, we hope to optimalize genetic counseling for patients with breast cancer: information customized to DNA results, shortening the period of uncertainty and the possibility of taking genetic advice into account for the treatment and follow-up of breast cancer.
- Main changes (audit trail)
- RECORD10-aug-2011 - 4-sep-2011


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl